The inhibition of human lung fibroblast proliferation and differentiation by Gs-coupled receptors is not predicted by the magnitude of cAMP response

Maxine J. Roberts¹, Rebecca E. Broome², Toby C. Kent², Steven J. Charlton¹,² and Elizabeth M. Rosethorne¹,²*

Abstract

Background: Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive fibrotic lung disease for which there is no cure. Current therapeutics are only able to slow disease progression, therefore there is a need to explore alternative, novel treatment options. There is increasing evidence that the 3′, 5′ cyclic adenosine monophosphate (cAMP) pathway is an important modulator in the development of fibrosis, with increasing levels of cAMP able to inhibit cellular processes associated with IPF. In this study we investigate the expression of Gs-coupled G protein-coupled receptors (GPCR) on human lung fibroblasts (HLF), and explore which can increase cAMP levels, and are most efficacious at inhibiting proliferation and differentiation.

Methods: Using TaqMan arrays we determined that fibroblasts express a range of Gs-coupled GPCR. The function of selected agonists at expressed receptors was then tested in a cAMP assay, and for their ability to inhibit fibroblast proliferation and differentiation.

Results: Expression analysis of GPCR showed that the prostacyclin, prostaglandin E₂ (PGE₂) receptor 2 and 4, melanocortin-1, β₂ adrenoceptor, adenosine 2B, dopamine-1, and adenosine 2A receptors were expressed in HLF. Measuring cAMP accumulation in the presence of selected Gs-coupled receptor ligands as well as an adenyl cyclase activator and inhibitors of phosphodiesterase showed formoterol, PGE₂, treprostinil and forskolin elicited maximal cAMP responses. The agonists that fully inhibited both fibroblast proliferation and differentiation, BAY60–6583 and MRE-269, were partial agonists in the cAMP accumulation assay.

Conclusions: In this study we identified a number of ligands that act at a range of GPCR that increase cAMP and inhibit fibroblast proliferation and differentiation, suggesting that they may provide novel targets to develop new IPF treatments. From these results it appears that although the cAMP response is important in driving the anti-fibrotic effects we have observed, the magnitude of the acute cAMP response is not a good predictor of the extent of the inhibitory effect. This highlights the importance of monitoring the kinetics and localisation of intracellular signals, as well as multiple pathways when profiling novel compounds, as population second messenger assays may not always predict phenotypic outcomes.

Keywords: cAMP, Idiopathic pulmonary fibrosis, Human lung fibroblasts, G protein-coupled receptors, Drug discovery
Background
Idiopathic pulmonary fibrosis (IPF) is an age-related, chronic and progressive fibrotic lung disease, with an annual incidence in the UK of 7.44 per 100,000 people, and a median survival of approximately 3 years from diagnosis [1]. The current hypothesis is that IPF is a consequence of aberrant wound healing in response to repetitive lung injury, resulting in fibrosis rather than repair. The dysregulation of the wound healing response is thought to cause the development of fibrosis through excess fibroblast proliferation, fibroblast to myofibroblast transdifferentiation (FMT), and extracellular matrix (ECM) deposition. In the IPF lung, aggregates of proliferating fibroblasts and myofibroblasts, termed “fibroblast foci”, are a key histopathological finding, which indicate that fibrosis is actively ongoing [2]. An increased accumulation of ECM and scarring in the lung, causes lung stiffness and compromises its ability to facilitate normal gas exchange [3].

A key therapeutic goal in the treatment of IPF is to reduce tissue fibrosis, which may be achieved by enhancing signals that counteract fibrotic processes, and/or inhibit signals and mediators that promote fibrosis. There are at present two drugs that are now approved for use in the treatment of IPF; nintedanib and pirfenidone. Nintedanib inhibits multiple receptor tyrosine kinases (RTK) [4] and pirfenidone has broad anti-inflammatory/anti-transforming growth factor β (TGFβ) activity [5, 6]. Although both nintedanib and pirfenidone have been shown to be efficacious in slowing the progression of disease [7–10], their non-specific action leads to severe adverse effects such as diarrhea, dyspnoea, vomiting and weight loss, that are dose limiting thereby restricting their use to the more severe patients. Research to identify alternative pathways in IPF treatment is essential to enable the development of safer, more efficacious and better tolerated drugs.

As RTK predominantly signal through the Ras/mitogen-activated protein kinase (MAPK) signalling cascade, it is likely that this pathway is responsible for many of the pro-fibrotic responses observed in IPF [11]. There is increasing evidence that the cyclic adenosine monophosphate (cAMP) pathway can negatively impact MAPK signalling, via inhibition of extracellular signal–regulated kinase (ERK) phosphorylation and activation in certain cell types [12, 13]. This suggests that activation of the cAMP pathway could provide novel targets to treat IPF. In support of this, a number of studies have shown that cAMP can negatively regulate fibroblast function, as agonists that bind to Gs-coupled G protein-coupled receptors (GPCR) thus activating adenylyl cyclase (AC) and increasing levels of cAMP, inhibit lung fibroblast migration, proliferation and differentiation. For example, prostaglandin E2 (PGE2) acting at PGE2 receptor 2 (EP2) and 4 (EP4) and iloprost acting at the prostacyclin (IP) receptor, were shown to have an inhibitory effect on proliferation and differentiation of lung fibroblasts, via cAMP accumulation and protein kinase A (PKA) activation [14–16]. Additionally, increasing levels of cAMP through direct activation of AC by forskolin inhibited the proliferation and differentiation of human embryonic fibroblasts [17]. Furthermore, inhibition of phosphodiesterases (PDE), which catalyse cAMP degradation, by roflumilast or cilomilast was shown to reduce pulmonary fibrosis in the bleomycin-induced mouse fibrosis model [18, 19].

The present study was performed in order to evaluate the anti-proliferative capacity of a range of Gs-coupled GPCR in order to identify potential new targets to treat IPF. We have explored the ability of Gs-coupled GPCR present in HLF to increase global cAMP using high-throughput compatible, homogenous assay kits. We have further explored how the observed increases in cAMP accumulation translate into an ability to inhibit fibroblast proliferation and differentiation, in order to determine whether any of the selected GPCR would be suitable for exploring further as novel targets to treat IPF.

Methods
Materials
Foetal bovine serum (FBS), trypsin-EDTA, Hoechst 33,342, RNAqueous kit, TURBO DNase and High Capacity RNA-to-cDNA kit were purchased from Life Technologies (Paisley, UK). CGS-21680, BMY-45778, BAY60-2755, iloprost, and NECA were purchased from Tocris (Abingdon, UK). Beraprost was bought from Cayman Chemical Company (Michigan, USA). PDGF-BB was purchased from R&D Systems (Minneapolis, USA). MRE-269 (CAS: 475085–57-5) and AGN-205204 (CAS:802906–77-0) were synthesized in house at Novartis (Horsham, UK). Phospho-p44/42 ERK1/2 (Thr202/Tyr204) (D13.14.4E) XP® Rabbit mAb primary antibody was purchased from Cell Signalling Technology (Leiden, The Netherlands). CF^647-conjugated Affini-pure goat anti-rabbit IgG and CF^647-conjugated Affini-pure goat anti-mouse IgG were purchased from Biotium, Inc., (Fremont, California). Pierce™ LDH Cytotoxicity Assay Kit and CellEvent™ Caspase-3/7 Red Detection Reagent were purchased from ThermoFisher (Hemel Hempstead, UK). Staurosporine was purchased from VWR International Ltd. (Lutterworth, UK). 96-well white ViewPlates, AlphaScreen cAMP and DELFIA proliferations assay kits were purchased from Perkin Elmer Life Sciences (Massachusetts, USA), 96-well black ViewPlates were purchased from Corning (New York, USA), and 384-well black μ-clear Viewplates were purchased from Greiner bio-one (Stonehouse, UK). HitHunter™ cAMP assay kits were purchased from DiscoverX (Birmingham, UK). All other reagents were purchased from Sigma Aldrich (Poole, UK).
Cell culture

All studies were performed on normal human lung fibroblasts (C-12361), which were purchased from Promocell (Heidelberg, Germany). HLF were maintained in DMEM supplemented with 4.5 g L\(^{-1}\) D-glucose, L-glutamine, pyruvate, FBS (10% v/v), and 25 mM HEPES at 37°C, 5% CO\(_2\), in a humidified atmosphere. For experiments cells were harvested using trypsin/EDTA and seeded in their sub-culture medium. Two HLF donors were used in the functional studies: HLF d91019001.2 and HLF 9017402.1, both from healthy/non-smoker Caucasian donors.

Receptor expression levels

Expression of GPCR was determined in HLF using high density, 384-well GPCR TaqMan arrays as previously described [20]. RNA from 4 fibroblast donors (all from healthy/non-smoker Caucasian donors) was isolated using the RNeasy kit and treated with TURBO DNase to remove genomic DNA. Using a High Capacity RNA-to-cDNA kit according to manufacturer’s instructions to synthesize cDNA. The GPCR array contained validated primer/probe sets for 367 GPCR. 100 ng of cDNA was loaded per port and the array was run on an Applied Biosystems 7900HT fast real-time PCR instrument according to the manufacturer’s instructions. 13 housekeeping genes were included as controls in the arrays for the purpose of quality control and data normalisation: (ACTB, β-actin; B2M, β-2-microglobulin; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GUSB, β-Glucuronidase; HMBS, hydroxymethylbilane synthase; HPRT1, hypoxanthine phosphoribosyltransferase 1; IPO8, importin 8; PGK1, phosphoglycerate kinase 1; PELL2A, RNA polymerase II subunit A; PPIA, peptidylprolyl isomerase A; RPLPO, ribosomal protein lateral stalk subunit P0; TBP, TATA-Box binding protein; TFRC, Transferrin Receptor). Data was analyzed using RQ manager version 1.2 and DataAssist version 2 (Applied Biosystems) with a Cycle Threshold (CT) set at 0.2 for all samples.

ERK phosphorylation

HLF were seeded overnight at 6000 cells/well in 96-well black clear bottom plates then starved for 24 h in the growth medium devoid of all additives. To assess ERK phosphorylation (pERK), cells were incubated in growth medium devoid of all additives (+ 0.1% HSA, sterile filtered) for 30 min with a range of concentrations of forskolin. After this time, cells were stimulated with an EC\(_{80}\) concentration of PDGF (3 ng/mL) for 10 min, at 37°C. 5% CO\(_2\). After stimulation, cells were fixed in 4% paraformaldehyde, washed 3x in PBS (with Ca\(^{2+}/\)Mg\(^{2+}\)), and incubated with permeabilising blocking buffer (dPBS (with Ca\(^{2+}/\)Mg\(^{2+}\)), 10% FBS (v/v), 0.1% Triton X-100 (v/v)) for 1 h at 37°C. Wells were then washed 3x in wash buffer (Tris Buffered Saline (TBS), 0.05% (v/v) Tween-20) and incubated with rabbit anti-pERK1/2 antibody (1:1000 dilution in blocking buffer overnight at 4°C. Following 3x wash in wash buffer, wells were incubated with blocking buffer containing Hoechst to stain for nuclear DNA (2 μM), and FITC-conjugated Affini-pure goat anti-rabbit IgG (1:1000 dilution in blocking buffer) for 30 min at 37°C. Fluorescence was then quantified on the InCell2000, using DAPI settings to visualize nuclei (0.1 s exp) and FITC settings for pERK (2 s exp).

To quantify levels of pERK fluorescence, a standard Multi-Target Analysis algorithm was used in the INCell Analyzer Workstation (v3.7.1). To account for the inter-assay variation in levels of ERK phosphorylation produced in each experiment, data were normalized to the EC\(_{80}\) PDGF response.

cAMP accumulation

HLF were grown to confluence in 96-well white View-Plates, before incubation with a range of agonist concentrations, or vehicle, for 2 h at room temperature in HBSS with 5 mM HEPES, 0.1% w/v HSA, and 5 μM rolipram. Rolipram was included in these assays to inhibit PDE activity, which resulted in increased maximal responses of cAMP accumulation, without any effect on EC\(_{50}\) values generated (data not shown). Rolipram was excluded when measuring cAMP levels in response to PDE inhibitors. cAMP levels were measured using either HitHunter cAMP assay or AlphaScreen competition assay following manufacturer protocol, and were assessed on either a BMG LABTEK ClarioStar or a Packard EnVision plate reader. cAMP concentrations in each well were determined using a standard curve. To account for the inter-assay variation in levels of cAMP produced in each experiment, data were normalized to the maximal forskolin response.

Proliferation

Proliferation of HLF was measured by incorporation of bromodeoxyuridine (BrdU). HLF were seeded overnight at 4000 cells/well in 96-well black ViewPlates, before being starved for 24 h in culture medium devoid of FBS. Proliferation was measured after incubation with a range of concentrations of FBS or PDGF, in DMEM supplemented with 0.1% w/v HSA, for 24 h.

For anti-remodelling assays using BrdU incorporation, cells were incubated for 24 h with a range of concentrations of test compounds in the presence of near maximal concentrations of FBS or PDGF in DMEM supplemented with 0.1% w/v HSA. Proliferation was assessed using the DELFIA BrdU incorporation assay kit following manufacturer protocol. Fluorescence was measured using a Packard EnVision plate reader. To account for
the inter-assay variation in levels of proliferation in each experiment, data were normalized to the PDGF or FBS response.

**Fibroblast to myofibroblast transdifferentiation**

To assess the differentiation of fibroblasts to the myofibroblast phenotype, immunofluorescence was used to monitor increases in α smooth muscle actin (αSMA). HLF were seeded overnight at 1000 cells/well in 384-well black clear bottom plates, before being starved for 24 h growth medium devoid of FBS.

For anti-remodelling assays using FMT, cells were incubated for 48 h with a range of concentrations of test compounds and incubated for 48 h, at 37°C, 5% CO₂ in the presence of a near maximal concentration of TGFβ (0.3 ng/mL), to promote differentiation in in DMEM supplemented with 0.1% w/v HSA. Following stimulation, cells were fixed in 4% paraformaldehyde, washed 3x in PBS (with Ca²⁺/Mg²⁺), and incubated with permeabilising blocking buffer (dPBS (with Ca²⁺/Mg²⁺), 10% FBS (v/v), 0.1% Triton X-100 (v/v)) for 1 h at 37°C. Wells were then washed 3x in wash buffer (Tris Buffered Saline (TBS), 0.05% (v/v) Tween-20) and incubated with mouse anti-αSMA (1:1000 dilution in permeabilising blocking buffer) for 1 h at room temperature, with gentle shaking. Following 3x wash in wash buffer, wells were incubated with blocking buffer containing Hoechst to stain for nuclear DNA (2 μM), and FITC-conjugated Affini-pure goat anti-rabbit IgG (1:1000 dilution in blocking buffer) for 30 min at 37°C. Fluorescence was then quantified on a widefield ImageXpress Micro microscope, with a Plan Fluor 20X objective, DAPI filter cube (excitation 400–418 nm, emission 435–470 nm), 50 ms exposure time for nuclei, and FITC filter cube (excitation 467–498 nm, emission 513–556 nm), 200 ms exposure time for αSMA.

To quantify increases in αSMA fluorescence, a standard Multi-Wavelength Cell Scoring algorithm was used in MetaXpress 5.3 software (Molecular Devices, California, USA). To account for the inter-assay variation in levels of αSMA expression produced in each experiment, data were normalized to the response to TGFβ.

**Data analysis**

Data were analysed using GraphPad Prism (Version 7.00) and results expressed as mean ± standard error of mean (SEM), unless otherwise stated. Concentration-response data were fitted using a four-parameter logistic equation. Expression of GPCR mRNA is reported as ΔC_T compared to the mean Cycle Threshold (CT) of the housekeeping genes and each value is the mean ± SD of 4 biological replicates. The Pearson correlation coefficient (r) was determined using the standard correlation function in GraphPad prism, followed by a two-tailed T test to determine significance.

**Results**

**Role of cAMP in the inhibition of ERK phosphorylation, and ERK phosphorylation in proliferation**

We first aimed to determine whether cAMP accumulation leads to inhibition of the pERK signal cascade in HLF, which may in turn suggest a role for cAMP in the inhibition of proliferation. Inhibition of ERK phosphorylation by the MEK inhibitor PD0325901 blocked PDGF-mediated proliferation of HLF. In turn forskolin, which increases cAMP through direct activation of AC, inhibited PDGF-mediated ERK phosphorylation (Fig. 1). For this reason, we explored the expression of GPCR in HLF, in order to determine which receptors would have the potential to increase cAMP and hence inhibit HLF proliferation and differentiation.

**GPCR expression in HLF**

We first established the expression profile of GPCR mRNA in HLF (See Additional file 1: Table S1) to select receptors to study further. All GPCR tested were characterised according to the canonical G protein pathway they are reported to couple to [21]. The Gs-coupled receptors expressed in HLF from high expression to low expression were IP, EP₂, melanocortin-1 (MC₁), β₂ adrenoceptor, adenosine 2B (A₂B), EP₄, dopamine-1, and adenosine 2A (A₂A) (Table 1).

The IP receptor was expressed at the highest level, with 2TO-ΔC_T of 0.053, approaching twice as much as the second highest expressed receptor EP₂, with 2TO-ΔC_T of 0.029. All the other receptors expressed had 2TO-ΔC_T that ranged from 0.012 for the MC₁ receptor to 0.002 for the A₂A receptor. Based on these results, a range of ligands were chosen that target these receptors (Table 2).
cAMP signalling in HLF

In order to investigate the functional activity of the receptors that demonstrated expression at the mRNA level, cAMP accumulation was measured in HLF in the presence of selected Gs-coupled GPCR agonists (Fig. 2). cAMP was monitored using commonly used, high throughput compatible, homogenous assay systems that allow quantification of cAMP in both cell media and lysates. In addition, cAMP accumulation was also investigated through direct activation of AC and inhibition of PDE, using forskolin and IBMX or rolipram, respectively. The majority of agonists tested increased cAMP levels in a concentration-dependent manner, with a range of potencies and efficacies (see Table 3). However, targeting the A2A receptor with CGS21680 and the MC1 receptor with α-MSH resulted in no detectable cAMP response. Furthermore, inhibiting PDE with IBMX or rolipram resulted in no detectable cAMP accumulation. Forskolin, formoterol, treprostinil, PGE2 and iloprost were fully efficacious in this assay, with other ligands giving partial responses that ranged from 8.76 to 83.3% of the forskolin response.

Proliferation

To determine if the cAMP response we observed in HLF was able to inhibit processes associated with airway remodelling, we investigated the ability of the same range of Gs-coupled GPCR agonists, as well as PDE inhibitors and AC activators, to inhibit HLF proliferation.

We first monitored cell number over time using a nuclei count assay after treatment with a range of concentrations of FBS or PDGF for 24, 48, 72, or 96 h (Additional file 1: Figure S2). There was no detectable increase in number of HLF after 24 h treatment with either of the stimuli used. FBS was capable of stimulating proliferation in a concentration-dependent manner at 48, 72 and 96 h (Additional file 1: Figure S2A), with EC50 of 0.62 ± 0.08% v/v at 48 h, and estimated EC50 of 3.42 ± 0.77% v/v, and 4.97 ± 0.92% v/v, respectively. In contrast, when treated with PDGF, HLF proliferation was only observed after 72 and 96 h treatment, with EC50 of 3.77 ± 0.13 ng/ml and 7.26 ± 3.23 ng/ml, respectively (Additional file 1: Figure S2B). The PDGF response was partial compared to the FBS response, with maximal proliferation of 29.2 ± 15.2% of the maximal serum response observed after 96 h treatment.

HLF were then treated for 48 h with a range of concentrations of ligands in the presence of an FBS concentration (1.8% v/v) that relates to near maximal proliferation (as determined from Additional file 1: Figure S2A). Agonists and PDE inhibitors inhibited FBS-driven proliferation with varying levels of efficacy and potency, however, full concentration-response curves could not be established for most agonists (Additional file 1: Figure S2A). The PDGF response was partial compared to the FBS response, with maximal proliferation of 29.2 ± 15.2% of the maximal serum response observed after 96 h treatment.

HLF were then treated for 48 h with a range of concentrations of ligands in the presence of an FBS concentration (1.8% v/v) that relates to near maximal proliferation (as determined from Additional file 1: Figure S2A). Agonists and PDE inhibitors inhibited FBS-driven proliferation with varying levels of efficacy and potency, however, full concentration-response curves could not be established for most agonists (Additional file 1: Figure S2A), and therefore accurate EC50 and Emax values could not be deduced. For this reason, we explored the use of an alternative assay to monitor fibroblast proliferation.

By monitoring BrdU incorporation into newly synthesized DNA of actively proliferating cells, we demonstrated that treatment of HLF with FBS or PDGF resulted in increases in proliferation in a concentration-dependent manner after 24 h incubation (Fig. 3). Similar to the nuclei

---

**Table 1** Ligands used in these studies

| Ligand     | Target         | Mechanism of action |
|------------|----------------|---------------------|
| Iloprost   | IP = EP1 > EP3 > FP > EP4 > TP > EP2 | Agonist             |
| Treprostinil| EP2 > EP3 > EP4 > EP1 > TP > FP     | Agonist             |
| MRE-269    | IP             | Agonist             |
| BMY-45778  | IP             | Agonist             |
| Beraprost  | IP             | Agonist             |
| PGE2       | EP1,4          | Agonist             |
| Misoprostol| EP2 > EP3 > EP4 > EP1 | Agonist             |
| Butaprost  | EP2, EP4       | Agonist             |
| AGN-205204 | EP4            | Agonist             |
| α-MSH      | MC1, MC3, MC4, MC5 | Agonist             |
| Formoterol | β2            | Agonist             |
| Indacaterol| β2            | Agonist             |
| Salbutamol | β2            | Agonist             |
| Salmeterol | β2            | Agonist             |
| NECA       | A3, A1, A2A, A2B | Agonist             |
| CGS-21680  | A2A           | Agonist             |
| BAY60–6583 | A2B           | Agonist             |
| Dopamine   | D1 = D3 > D4 > D2 > D4 | Agonist             |
| Forskolin  | AC 1–8        | Activator           |
| IBMX       | PDE4, PDE6, PDE1, PDE3, PDE2 | Inhibitor          |
| Rolipram   | PDE4          | Inhibitor           |

**Table 2** Expression analysis of selected GPCR in normal HLF

| Receptor | Expression (2 TO – ΔCT) |
|----------|-------------------------|
| IP       | 0.053 ± 0.016           |
| EP2      | 0.029 ± 0.001           |
| MC1      | 0.012 ± 0.002           |
| β2       | 0.008 ± 0.004           |
| A2B      | 0.007 ± 0.003           |
| EP4      | 0.004 ± 0.002           |
| Dopamine-1| 0.004 ± 0.001         |
| A2A      | 0.002 ± 0.001           |

Expression analysis of endogenously expressed Gs-coupled receptors in HLF. High density 384-well GPCR TaqMan arrays were run on normal HLF to monitor the expression of a range of Gs-coupled receptors. Expression is reported as 2 TO - ΔCT compared to the mean Cycle Threshold (Ct) of the 13 housekeeping genes that were included as controls in the arrays, and each value is the mean ± SD of 4 biological replicates.
count assays, PDGF was partial in comparison to FBS, with maximal proliferation of 41.0 ± 8.62% and 112 ± 5.49% for PDGF and FBS respectively.

HLF were then treated for 24 h with a range of concentrations of ligands in the presence of near maximal concentration of FBS or PDGF (as determined from Fig. 3). Targeting the IP, EP₂, EP₄, β₂, A₂B, and dopamine receptors, as well as activating AC, inhibited HLF proliferation with varying degrees of intrinsic activity and potency (Table 3; Figs. 4 and 5). When inhibiting serum-driven proliferation, ligands achieved maximal levels of inhibition ranging from 100% for BAY60–6583 to 29% for butaprost. After treatment with PDGF maximal levels of inhibition ranged from 100% for BAY60–6583 to 38% for NECA. BAY60–6583 was the only ligand to fully inhibit both FBS- and PDGF-driven proliferation, with other ligands being more efficacious at inhibiting PDGF-driven proliferation. α-MSH and rolipram were incapable of inhibiting the proliferation mediated by either stimulus.

In order to confirm that test compounds were directly inhibiting HLF proliferation rather than promoting cell death, cell viability was measured using the presence of caspase-3/7 as markers of apoptosis. None of the compounds tested caused a significant increase in expression of caspase-3/7, whereas treatment with the toxic compound staurosporine resulted in statistically significant cell apoptosis (P < 0.001) (See Additional file 1: Table S2).

**Fibroblast to myofibroblast transdifferentiation**

IPF is driven by a number of pro-fibrotic processes, therefore we next aimed to determine if the same agonists were also capable of inhibiting another key component of fibrosis, TGFβ-induced FMT. TGFβ is a key driver of fibrosis.

---

**Fig. 2** Receptor-mediated cAMP accumulation. Concentration effect curves for cAMP accumulation in HLF after treatment with a range of agonists targeting (a) IP receptor, (b) EP receptor, (c) β₂ adrenoceptor, (d) other GPCR and (e) non-receptors. Data for each individual experiment were normalized to maximal cAMP accumulation observed with 10 µM forskolin, and are expressed as mean ± SEM for at least 3 independent experiments.
and was able to robustly promote FMT in HLF with EC_{50} equal to 0.07 ± 0.01 ng/mL (data not shown).

In order to test the ability of compounds to inhibit FMT, HLF were treated for 48 h with a range of concentrations of the selected ligands in the presence of a TGFβ concentration (0.3 ng/mL) that relates to near maximal FMT. Agonists and PDE inhibitors inhibited TGFβ-driven FMT with varying levels of efficacy and potency (Fig. 6), however, full concentration-response curves could not be established for NECA, dopamine, α-MSH, IBMX or rolipram. Of the agonists tested, MRE-269, Bay 60–6583 and forskolin were able to completely inhibit FMT. All other ligands were able to partially inhibit FMT, with maximal levels of inhibition ranging from 71% of the TGFβ response for AGN205204 to 51% of the TGFβ response for salmeterol.

**Correlation between cAMP and the inhibition of proliferation and differentiation**

Because the assays like the simple, homogenous second messenger system used here are often utilised in high

![](image.png)

**Fig. 3** Fibroblast proliferation. Concentration-dependent increase in HLF proliferation following treatment with serum or PDGF for 24 h, assayed using BrdU incorporation. Data were normalized to maximal proliferation observed with 10% serum, and expressed as mean ± SEM for 8 independent experiments.
throughput screening to identify novel agonists for cAMP accumulation, we wanted to explore the relevance of this method for predicting the inhibition of HLF proliferation and differentiation. To do this, we generated correlation plots for maximal levels of cAMP generation against the maximal inhibition of proliferation or FMT (Fig. 7). There was no significant correlation between the amount of cAMP accumulation and the degree of inhibition of PDGF-mediated proliferation ($r^2 = 0.06$, $p = 0.41$), or TGFβ-mediated FMT ($r^2 = 0.06$, $p = 0.46$). This was most apparent with formoterol and treprostinil, which despite generating high levels of cAMP were relatively ineffective at inhibiting proliferation and differentiation. In contrast, BAY60–6583 and MRE-269 exhibited higher efficacy for the inhibition of proliferation and FMT than cAMP accumulation.

**Discussion**

IPF is a devastating disease, and with current therapeutics only able to slow disease progression and being associated with severe side effects, further research in IPF aetiology and drug discovery is urgently required. A key feature of IPF is airway remodelling which is driven by fibroblast proliferation and differentiation. This leads to the formation of fibroblast and myofibroblast foci that secrete excessive amounts of extracellular matrix resulting in airway stiffening and loss of pulmonary function. It is this airway remodelling that is associated with disease severity [2, 22] suggesting that targeting the inhibition of key fibroblast activities may lead to novel therapeutic approaches for IPF. There is an evolving body of evidence demonstrating cAMP as a potential target for the treatment of IPF, however it is unclear...
how acute cAMP accumulation is able to affect the chronic phenotypic responses involved in fibrosis, such as cell proliferation and differentiation.

Approved therapies and novel approaches undergoing clinical trials in IPF take the approach of inhibiting a range of pro-fibrotic stimuli, often GF-RTK combinations that predominantly signal via the MAPK pathway. Using fibroblast proliferation to model aspects of lung fibrosis, we demonstrated that inhibition of the MAPK pathway completely blocked PDGF-mediated proliferation, and that ERK phosphorylation could be completely inhibited by increasing global cAMP. For this reason, we wanted to explore the expression of Gs-coupled GPCR in HLF, as well as their ability to increase cAMP and subsequently inhibit HLF proliferation and differentiation in order to identify new targets to treat IPF that will complement existing therapies.

We observed mRNA expression of a number of different Gs-coupled GPCR in fibroblasts, including related receptor families such as those for prostaglandins (IP, EP2, EP4) and adenosine (A2A and A2B), as well as the MC1, β2 adrenoceptor and dopamine-1 receptors. Importantly, not all of these receptors resulted in functional cAMP responses, as measured by high throughput, homogenous assay systems. This highlights the need to look not only at mRNA levels, but protein expression and function as well to confirm active receptors are present.

To model chronic aspects of IPF we chose to study HLF proliferation and differentiation, as HLF are key mediators of fibrosis and contain human receptors and

**Fig. 5** Receptor-mediated inhibition of PDGF-mediated proliferation. Concentration effect curves for the inhibition of proliferation were determined in HLF following exposure to a range of agonists targeting the (a) IP receptor, (b) EP receptor, (c) β2 adrenoceptor, (d) other GPCR and (e) non-receptors, in the presence of an EC80 concentration of PDGF for 24 h. For each individual experiment, data were normalised to the maximal proliferation observed with PDGF, and are expressed as means ± SEM for at least 3 independent experiments.
Receptor-mediated inhibition of TGFβ-mediated FMT. Concentration effect curves for the inhibition of FMT were determined in HLF following exposure to a range of agonists targeting the (a) IP or EP receptors, (b) β2 adrenoceptor, (c) other GPCR and (d) non-receptors, in the presence of an EC80 concentration of TGFβ for 48 h. For each individual experiment, data were normalised to the maximal levels of FMT observed with TGFβ, and are expressed as means ± SEM for 4 independent experiments.

Correlation plot. Correlation between global cAMP accumulation and maximal inhibition of PDGF-mediated proliferation (a) or TGFβ-mediated FMT (b). Pearson correlation, dashed line = line of unity.
signalling proteins at relevant levels. Proliferation was monitored using two complimentary methods, BrdU incorporation into newly synthesized DNA of actively proliferating cells, and direct cell counting. Differentiation was monitored using an FMT assay that measures the increased expression of αSMA that indicates a myofibroblast phenotype. Using the BrdU incorporation assay we were able to quantify proliferation in response to both PDGF and serum (which contains multiple growth factors and proliferative stimuli) at an earlier stage compared to the cell counting method. This is likely due to the different sensitivities of the assays as well as the time course of responses being measured. We also observed that full concentration-response curves for the inhibition of cell counting could not be obtained for all ligands. For this reason, we focused on the BrdU incorporation and FMT assays to explore the responses further.

Using these models, we have demonstrated that selected agonists for the IP, β2, EP2, EP4, and A2B receptors, as well as forskolin, an activator of AC, were able to robustly inhibit HLF proliferation and differentiation. Interestingly, some agonists such as MRE-269, AGN205204 and BAY 60–6583 were able to fully inhibit either proliferation or FMT, despite being partial agonists for cAMP accumulation. This demonstrates that many of the agonists we have tested in this study have the potential to inhibit multiple processes that contribute to IPF clinically. It is important to note however that these studies were performed on fibroblasts from healthy donors, and therefore these results should be confirmed in fibroblasts from IPF patients, which may differ in their established phenotype.

We were able to demonstrate using both fibroblast proliferation and differentiation that cAMP accumulation does not correlate with the degree of inhibition of chronic phenotypic responses. This highlights the importance of developing novel treatments for IPF on the basis of their chronic effects rather than acute cAMP responses. For example, although iloprost has been described as a potential treatment for IPF due to its protective effects against bleomycin-induced pulmonary fibrosis in mice [23], our data suggests this may not be the optimal IP agonist for the treatment of IPF.

A number of the GPCR we identified here have previously been implicated in the treatment of IPF or other chronic lung diseases. The endogenous EP receptor agonist PGF2α has been shown to inhibit cellular markers of fibrosis [14, 16], and its synthetic analogue 16, 16-dimethyl-PGF2 protects against bleomycin induced injury [24]. This coupled with diminished PGF2α signalling in lung fibrosis [25], and the strong inhibition of proliferation we observe with selective agonists suggests that EP2 &/or EP4 agonists are strong candidates for novel IPF treatments. Recent studies have also identified the A2B receptor as an important target in the regulation of both acute and chronic lung disease, with agonists being considered for the treatment of acute lung injury and antagonists being considered for the treatment of chronic lung diseases [26–28]. In agreement with these findings, we observed that the selective A2B agonist BAY 60–6583, although not very potent, showed robust inhibition of HLF proliferation.

Currently, inhaled β2 adrenoceptor agonists are widely used for the treatment of lung diseases such as chronic obstructive pulmonary disease (COPD), providing relief by inducing bronchodilation of airway smooth muscle. We have shown here that the long acting β2 adrenoceptor agonists’ salmeterol and indacaterol may also act as anti-fibrotic agents in IPF through the robust inhibition of HLF proliferation and differentiation.

Although we did not observe any acute cAMP accumulation with the PDE inhibitor IBMX, we did observe some inhibition of both proliferation and FMT at higher concentrations. In the isolated fibroblasts there may not be sufficient basal cAMP turnover in order for PDE inhibitors to substantially increase levels of cAMP during the shorter cAMP assay, but with the extended incubation for the phenotypic assays (24 or 48 h), IBMX may be able to cause some accumulation of cAMP that is driving this inhibitory effect. In support of this, PDE inhibitor use is being explored for IPF and they have been shown to be effective in the bleomycin model [18, 19]. It would therefore be interesting to determine whether co-administration with GPCR agonists could further boost the anti-proliferative capacity of the agonists tested here.

The mechanisms behind the apparent disconnect we observed between acute cAMP accumulation and inhibition of chronic phenotypic responses is not yet clear, however there are a number of factors that need to be considered. Firstly, proliferation and differentiation were monitored over a longer time period than the cAMP accumulation assays, so it is possible that the agonists tested were degrading over time leading to loss of response. We have previously demonstrated that for treprostinil and MRE-269 > 90% of the original concentration of agonist remains after 24 h incubation with HLF (unpublished data), suggesting that it is unlikely that ligand degradation is contributing to the effect we have seen.

Another aspect of GPCR signalling that may be contributing to the responses we have observed is the ability to signal through multiple G proteins or effector molecules. It has now been well characterized that β-arrin, once recruited to a GPCR, may initiate a cascade of G protein-independent signalling [29], the best characterized of which is the MAPK/ERK cascade. In these cells activation of cAMP signalling leads to inhibition of proliferation, most likely via inhibition of the ERK phosphorylation. This suggests that this promiscuous signalling is unlikely to be contributing to the disconnect we observed between...
cAMP and inhibition of proliferation, although it should be explored further. Forskolin was able to robustly inhibit both fibroblast proliferation and differentiation, further supporting a direct role for the cAMP pathway in the inhibition of these chronic phenotypic responses. It may be that the spatial or temporal control of these cAMP signals is more important in regulating downstream, chronic effects rather than the absolute levels of cAMP generated.

The temporal characteristics of the cAMP response can be controlled directly through the kinetics or duration of the cAMP response, or through time-dependent internalization and desensitization of activated receptors. Agonists such as treprostinil and iloprost which are full agonists in the cAMP accumulation assay may undergo a higher degree of desensitization than the partial agonist MRE-269. This could explain why there is a reversal of intrinsic activity for these ligands in the two assays. However, recent evidence from chronic cAMP studies suggests that regardless of their efficacy, all agonists will produce the same relative degree of functional desensitization [30]. In support of this, indacaterol, which elicits 80% maximal response in cAMP is as effective at inhibiting proliferation as the lower efficacy agonist salmeterol, which elicits a 40% maximal cAMP response. Interestingly, both these compounds are long-acting β2 adrenoceptor agonists, which suggests a role for signalling kinetics in mediating chronic phenotypic events. This has been demonstrated previously for the regulation of gene transcription after GPCR activation, where the kinetics or duration of second messenger responses was shown to drive transcriptional activity [31, 32].

Compartmentalized cAMP signalling may also contribute to receptor/ligand-dependent downstream effects. Selective activation of specific intracellular pools of cAMP can occur through physical intracellular barriers, such as the A-kinase-anchoring proteins (AKAP) [33–35], or through persistent signalling of agonist-receptor complexes after internalization. This persistent signalling has been described for the Gq-coupled S1P1 receptor [36] and more recently with the β2 adrenoceptor [37]. Further studies are required to determine if the duration and location of the cAMP signalling, rather than the magnitude, is important for long-term phenotypic responses.

**Conclusion**

In conclusion, in these studies we have demonstrated that selected agonists at the IP, β2, EP2, EP4, and A2B receptors have the potential to inhibit pro-fibrotic processes such as fibroblast proliferation and differentiation, implying a potential for disease modifying effects in IPF. From these results it appears that although the cAMP response is important in driving the anti-fibrotic effects we have observed, there appears to be a threshold of cAMP that is required to inhibit proliferation and differentiation over which any further increases of cAMP do not drive further inhibition. For this reason, the magnitude of acute, global cAMP accumulation does not accurately predict the degree of inhibition of proliferation or differentiation suggesting additional factors, such as the spatio-temporal control of cAMP are important. Further research is required to understand this disconnect, which will aid in the discovery of novel, therapeutically beneficial treatments for IPF.

**Additional file**

**Additional file 1**: Additional data describing full GPCR expression analysis in human lung fibroblasts and chemical structures of ligands used in these studies. Further characterization of these ligands in an imaging-based nuclear count assay and cell viability assay is presented. (DOCX 1357 kb)

**Abbreviations**

AA2A: Adenosine 2A; A2B: Adenosine 2B; AC: Adenyl cyclase; AKAP: A-kinase anchoring protein; cAMP: 3′,5′ cyclic adenosine monophosphate; COPD: Chronic obstructive pulmonary disease; CT: Cycle threshold; DMEM: Dulbecco’s modified eagle medium; dPBS: Dulbecco’s phosphate buffered saline solution; ECM: Extracellular matrix; ERK: Extracellular signal–regulated kinase; FBS: Foetal bovine serum; FMT: Fibroblast to myofibroblast transdifferentiation; FRET: Fluorescence resonance energy transfer; GF: Growth factor; GPCR: G protein-coupled receptors; HBSS: Hank’s Buffered Salt Solution; HLF: Human lung fibroblasts; HSA: Human serum albumin; IP: Prostacyclin; IPF: idiopathic pulmonary fibrosis; LDH: lactate dehydrogenase, MAPK: Mitogen-activated protein kinase; M1C: Melanocortin-1; PAH: Pulmonary arterial hypertension; PDE: Phosphodiesterase; PDGF: Platelet-derived growth factor; PFA: Parafomaldehyde; PGE2: Prostaglandin E2; PKA: Protein kinase A; RTK: Receptor tyrosine kinase; SEM: Standard error of mean; TGFβ: Transforming growth factor β; VEGF: Vascular endothelial growth factor; α-MSH: Alpha melanocortin stimulating hormone

**Acknowledgements**

Not applicable

**Funding**

This work was supported by the Novartis Institutes for Biomedical Research and the University of Nottingham.

**Availability of data and materials**

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Authors’ contributions**

Study Concept and Design: MJR, REB, SJC, EMR. Acquisition of Data: MJR, REB, TCK, EKR. Analysis and Interpretation of Data: MJR, REB, TCK, SJC, EMR. Drafting of Manuscript: MJR, SJC, EMR. Accountability for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: SJC, EMR. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

The human lung fibroblasts used in this study was sourced from PromoCell and were derived from donors who have signed an informed consent form (this being done by the donor himself, an authorized agent, or a legal agent) which outlines in detail the purpose of the donation and the procedure for processing the tissue. When obtaining and using human tissue, PromoCell acts in strict compliance with “The Convention for Protection of Human Rights and Dignity of the Human Being with Regard to the Application of Biology and Medicine: Convention of Human Rights and Biomedicine” published on April 4th, 1997 by the Council of Europe (European Treaty Series – no 164), “The Human Tissue Act” published on November 15th, 2004 by the government of the United Kingdom, the “The Declaration of Helsinki” developed by the World
Medical Association and the "German Federal Data Protection Act" to protect privacy of donors.

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 13 December 2017 Accepted: 27 March 2018
Published online: 07 April 2018

References
1. Navaratnam V, Fleming KM, West J, Smith CJ, Jenkins RG, Fogarty A, Hubbard RB. The rising incidence of idiopathic pulmonary fibrosis in the U.K. Thorax. 2011;66:462–7.
2. Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med. 1998;157.
3. Wolters PJ, Collard HR, Jones KD. Pathogenesis of idiopathic pulmonary fibrosis. Am Rev Pathol. 2014;157:79.
4. Chaudhary NI, Roth GJ, Hilberg F, Müller-Quernheim J, Prasse A, Zissel G, Schnapp A, Park JE. Inhibition of PDGF, VEGF, and FGF signaling attenuates fibrosis. Eur Respir J. 2007;29:976–85.
5. Iyer SN, Gunjeyyalakshmi G, Giri SN. Effects of Pirfenidone on transforming growth factor-β gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther. 1999;291:367–73.
6. Iyer SN, Hyde DM, Giri SN. Anti-inflammatory effect of Pirfenidone in the bleomycin-hamster model of lung inflammation. Inflammation. 2000;24:101–9.
7. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcburg J, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377:1760–9.
8. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Hansell DM, Inoue Y, et al. Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis: a randomised, controlled trial. Lancet. 2011;377:1760–9.
9. Richeldi L, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Albera C, Bradford WZ, Costabel U, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377:1760–9.
10. Mullershausen F, Zecri F, Cetin C, Billich A, Guerini D, Seuwen K. Persistent inhibition of PDGF, VEGF and FGF signalling attenuates acute lung injury by enhancing alveolar fluid clearance in mice. J Clin Invest. 2008;111:2173–82.
11. De Maeyer ML, Sekahara H, Nishiyama K, Kato J, Shiga T, Iwamura Y, et al. The anti-inflammatory effect of Pirfenidone: a randomized, double-blind, placebo-controlled, multicenter, Phase II study for idiopathic pulmonary fibrosis. Respirology. 2011;16:177–84.
12. Baker JG, Han PP, Hill SJ. Temporal characteristics of cAMP response element-mediated gene transcription: requirement for sustained cAMP production. Mol Pharmacol. 2004;65:986–98.
13. Dullaert W, Nakatsukasa N, Toft N, van der Weg M, Furlan A, Huybrechts O, et al. Pirfenidone for the non-invasive treatment of idiopathic pulmonary fibrosis: a randomized, placebo-controlled trial. N Engl J Med. 2011;365:1686–95.
14. Schermuly RT. Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice. BMC Pulm Med. 2010;10:26.
15. Groot-Kormelink PJ, Fawcett L, Wright PD, Gosling M, Kent TC. Quantitative GPCR and ion channel transcriptomics in primary alveolar macrophages and macrophage surrogate. BMC Genomics. 2012;13:57.
16. Alexander SP, Mathie A, Peters JA. Guide to receptors and channels (GRAC), 5th edition. Br J Pharmacol. 2011;164(Suppl 1):S1–324.
17. Talmadge EK, Schwarz MI, Brown K, Tooze JA, Colby TV, James AWJ, Flint A, Thurlbeck W, Cherniack RM. Idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001;164:1025–32.
18. Zhu Y, Liu Y, Zhou W, Xiang R, Jiang L, Huang K, Xiao Y, Guo Z, Gao J. A prostacyclin analogue, iloprost, protects from bleomycin-induced pulmonary fibrosis in mice. RespiRes. 2010;1:134.
19. Udalov S, Dumitrescu R, Pullamsetti SS, At-tamari HM, Weissmann N, Ghoftani HA, Guenther A, Voswinckel R, Seeger W, Grimminger F, Schermuly RT, et al. Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice. BMC Pulm Med. 2010;10:26.
20. Groot-Kormelink PJ, Fawcett L, Wright PD, Gosling M, Kent TC. Quantitative GPCR and ion channel transcriptomics in primary alveolar macrophages and macrophage surrogates. BMC Genomics. 2012;13:57.
21. Alexander SP, Mathie A, Peters JA. Guide to receptors and channels (GRAC), 5th edition. Br J Pharmacol. 2011;164(Suppl 1):S1–324.
22. Talmadge EK, Schwarz MI, Brown K, Tooze JA, Colby TV, James AWJ, Flint A, Thurlbeck W, Cherniack RM. Idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001;164:1025–32.
23. Zhu Y, Liu Y, Zhou W, Xiang R, Jiang L, Huang K, Xiao Y, Guo Z, Gao J. A prostacyclin analogue, iloprost, protects from bleomycin-induced pulmonary fibrosis in mice. RespiRes. 2010;1:134.
24. Failla M, Genovese T, Mazzon E, Fagone E, Gilli E, Barera A, La RC, Conte E, Crimi N, et al. 16,16-dimethyl prostaglandin E2 efficacy on prevention and protection from bleomycin-induced lung injury and fibrosis. AmJRespiCell MolBiol. 2009;40:50–8.